Literature DB >> 1558789

Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo.

C A Toth1, P Thomas.   

Abstract

A type I interferon resistant variant (beta-MIP101) of the poorly differentiated human colon cancer cell MIP101 has a more aggressive phenotype in vivo in the nude mouse. Subcutaneous tumours grew at twice the rate of MIP101, but with similar morphology. beta-MIP101 also produced liver metastases at a higher frequency. beta-MIP101 tumours were diploid while MIP101 tumours were aneuploid. Both cell lines had doubling times of approximately 25 h in vitro.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1558789      PMCID： PMC1977610          DOI： 10.1038/bjc.1992.74

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  17 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.

Authors:  S Wadler; M Goldman; A Lyver; P H Wiernik
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

Review 3.  Interferon receptors.

Authors:  A A Branca
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

4.  Characterization of the synergistic antiproliferative effects of interferon-gamma and tumor necrosis factor on human colon carcinoma cell lines.

Authors:  J H Schiller; B Storer; G Bittner; M A Horisberger
Journal:  J Interferon Res       Date:  1990-04

5.  Characterization of the tumorigenic and metastatic potential of a poorly differentiated human colon cancer cell line.

Authors:  H E Wagner; P Thomas; B C Wolf; N Zamcheck; J M Jessup; G D Steele
Journal:  Invasion Metastasis       Date:  1990

6.  Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.

Authors:  J L Abbruzzese; B Levin; J A Ajani; J S Faintuch; S Saks; Y Z Patt; C Edwards; K Ende; J U Gutterman
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

7.  Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.

Authors:  S Wadler; R Wersto; V Weinberg; D Thompson; E L Schwartz
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

8.  The effect of interferon treatment on 14 human colorectal cancer cell lines: growth and carcinoembryonic antigen secretion in vitro.

Authors:  C A Toth; P Thomas
Journal:  J Interferon Res       Date:  1990-12

9.  Isolation and characterization of an undifferentiated human colon carcinoma cell line (MIP-101).

Authors:  R M Niles; S A Wilhelm; G D Steele; B Burke; T Christensen; D Dexter; M J O'Brien; P Thomas; N Zamcheck
Journal:  Cancer Invest       Date:  1987       Impact factor: 2.176

10.  Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.

Authors:  J A Ajani; A A Rios; K Ende; J L Abbruzzese; C Edwards; J S Faintuch; S Saks; J U Gutterman; B Levin
Journal:  J Biol Response Mod       Date:  1989-04
View more
  3 in total

1.  Expression profiling and interferon-beta regulation of liver metastases in colorectal cancer cells.

Authors:  Regis Zimmer; Peter Thomas
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 2.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.

Authors:  Wei-Choong Ch'ng; Eric J Stanbridge; Khatijah Yusoff; Norazizah Shafee
Journal:  J Interferon Cytokine Res       Date:  2013-03-18       Impact factor: 2.607
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.